Evidence map›Paper›PMID 35510852›Full record

ArticleMicrobiology spectrum2022

SARS-CoV-2 Infection of Microglia Elicits Proinflammatory Activation and Apoptotic Cell Death.

Gi Uk Jeong, Jaemyun Lyu, Kyun-Do Kim, Young Cheul Chung, Gun Young Yoon, Sumin Lee, Insu Hwang, Won-Ho Shin, Junsu Ko, June-Yong Lee and 1 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 2 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Gi Uk JeongCenter for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technologygrid.29869.3c, Daejeon, Republic of Korea.
Jaemyun LyuArontier Co., Ltd., Seoul, Republic of Korea.
Kyun-Do KimCenter for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technologygrid.29869.3c, Daejeon, Republic of Korea.
Young Cheul ChungDepartment of Predictive Toxicology, Korea Institute of Toxicology, Daejeon, Republic of Korea.
Gun Young YoonCenter for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technologygrid.29869.3c, Daejeon, Republic of Korea.
Sumin LeeCenter for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technologygrid.29869.3c, Daejeon, Republic of Korea.
Insu HwangCenter for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technologygrid.29869.3c, Daejeon, Republic of Korea.
Won-Ho ShinDepartment of Predictive Toxicology, Korea Institute of Toxicology, Daejeon, Republic of Korea.
Junsu KoArontier Co., Ltd., Seoul, Republic of Korea.
June-Yong LeeDepartment of Microbiology and Immunology, College of Medicine, Yonsei Universitygrid.15444.30, Seoul, Republic of Korea.
Young-Chan KwonCenter for Convergent Research for Emerging Virus Infection, Korea Research Institute of Chemical Technologygrid.29869.3c, Daejeon, Republic of Korea.ORCID 0000-0003-1100-5168
Korea Research Institute of Chemical Technology · KRBiology of Infection · FRKorea Institute of Toxicology · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes various neurological symptoms in patients with coronavirus disease 2019 (COVID-19). The most dominant immune cells in the brain are microglia. Yet, the relationship between neurological manifestations, neuroinflammation, and host immune response of microglia to SARS-CoV-2 has not been well characterized. Here, we reported that SARS-CoV-2 can directly infect human microglia, eliciting M1-like proinflammatory responses, followed by cytopathic effects. Specifically, SARS-CoV-2 infected human microglial clone 3 (HMC3), leading to inflammatory activation and cell death. RNA sequencing (RNA-seq) analysis also revealed that endoplasmic reticulum (ER) stress and immune responses were induced in the early, and apoptotic processes in the late phases of viral infection. SARS-CoV-2-infected HMC3 showed the M1 phenotype and produced proinflammatory cytokines, such as interleukin (IL)-1β, IL-6, and tumor necrosis factor α (TNF-α), but not the anti-inflammatory cytokine IL-10. After this proinflammatory activation, SARS-CoV-2 infection promoted both intrinsic and extrinsic death receptor-mediated apoptosis in HMC3. Using K18-hACE2 transgenic mice, murine microglia were also infected by intranasal inoculation of SARS-CoV-2. This infection induced the acute production of proinflammatory microglial IL-6 and TNF-α and provoked a chronic loss of microglia. Our findings suggest that microglia are potential mediators of SARS-CoV-2-induced neurological problems and, consequently, can be targets of therapeutic strategies against neurological diseases in patients with COVID-19.

Indexed as

ApoptosisCOVID-19MicrogliaAnimalsCell LineCytokinesHumansInterleukin-6MiceMice, TransgenicSARS-CoV-2Tumor Necrosis Factor-alphaCytokinesInterleukin-6Tumor Necrosis Factor-alphaapoptosisM1 polarizationmicroglianeuroinflammationSARS-CoV-2

Identifiers

PMID35510852
PMCPMC9241873
OpenAlexW4229060333

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.